Roche pays Repare $125M to join Big Pharma peers in cancer race

Roche is joining AstraZeneca, Bayer, Merck KGaA and more in a synthetic lethality race, paying Repare Therapeutics $125 million upfront for an ATR inhibitor with monotherapy and combination applications in indications such as ovarian cancer.